Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: MarketLine (a Datamonitor Company)
$175.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Astellas Pharma Inc. Announces Approval in Japan for Treating Functional Dyspepsia with Acofide


Monday, 25 Mar 2013 02:00am EDT 

ZERIA PHARMACEUTICAL CO LTD and Astellas Pharma Inc. announced today that as of March 25, Zeria has obtained the marketing approval of Acofide Tablets 100mg (nonproprietary name: acotiamide hydrochloride hydrate;) for the treatment of functional dyspepsia (FD) from the Ministry of Health, Labour and Welfare in Japan.Acofide has been co-developed by both companies. 

Company Quote

1399.5
-12.0 -0.85%
24 Jul 2014